Literature DB >> 33946954

Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy.

Rasa Islam1,2, Aleta Pupovac1, Vera Evtimov1, Nicholas Boyd1, Runzhe Shu1, Richard Boyd1, Alan Trounson1,2.   

Abstract

Natural killer (NK) cells are potent innate immune system effector lymphocytes armed with multiple mechanisms for killing cancer cells. Given the dynamic roles of NK cells in tumor surveillance, they are fast becoming a next-generation tool for adoptive immunotherapy. Many strategies are being employed to increase their number and improve their ability to overcome cancer resistance and the immunosuppressive tumor microenvironment. These include the use of cytokines and synthetic compounds to bolster propagation and killing capacity, targeting immune-function checkpoints, addition of chimeric antigen receptors (CARs) to provide cancer specificity and genetic ablation of inhibitory molecules. The next generation of NK cell products will ideally be readily available as an "off-the-shelf" product and stem cell derived to enable potentially unlimited supply. However, several considerations regarding NK cell source, genetic modification and scale up first need addressing. Understanding NK cell biology and interaction within specific tumor contexts will help identify necessary NK cell modifications and relevant choice of NK cell source. Further enhancement of manufacturing processes will allow for off-the-shelf NK cell immunotherapies to become key components of multifaceted therapeutic strategies for cancer.

Entities:  

Keywords:  allogeneic immunotherapy; cancer; natural killer (NK) cells; pluripotent stem cells

Year:  2021        PMID: 33946954     DOI: 10.3390/cells10051058

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  178 in total

1.  Differential subcellular targeting and activity-dependent subcellular localization of diacylglycerol kinase isozymes in transfected cells.

Authors:  Naoki Kobayashi; Yasukazu Hozumi; Tsukasa Ito; Takaaki Hosoya; Hisatake Kondo; Kaoru Goto
Journal:  Eur J Cell Biol       Date:  2007-06-27       Impact factor: 4.492

2.  Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.

Authors:  E Liu; Y Tong; G Dotti; H Shaim; B Savoldo; M Mukherjee; J Orange; X Wan; X Lu; A Reynolds; M Gagea; P Banerjee; R Cai; M H Bdaiwi; R Basar; M Muftuoglu; L Li; D Marin; W Wierda; M Keating; R Champlin; E Shpall; K Rezvani
Journal:  Leukemia       Date:  2017-07-20       Impact factor: 11.528

3.  Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial.

Authors:  Stefan W Krause; Robert Gastpar; Reinhard Andreesen; Catharina Gross; Heidrun Ullrich; Gerald Thonigs; Karin Pfister; Gabriele Multhoff
Journal:  Clin Cancer Res       Date:  2004-06-01       Impact factor: 12.531

4.  A phase I/II trial of interleukin-15--stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors.

Authors:  Antonio Pérez-Martínez; Lucía Fernández; Jaime Valentín; Isabel Martínez-Romera; María Dolores Corral; Manuel Ramírez; Lorea Abad; Sandra Santamaría; Marta González-Vicent; Sara Sirvent; Julián Sevilla; José Luis Vicario; Inmaculada de Prada; Miguel Ángel Diaz
Journal:  Cytotherapy       Date:  2015-09-01       Impact factor: 5.414

5.  TriKEs and BiKEs join CARs on the cancer immunotherapy highway.

Authors:  Szun Szun Tay; Hernan Carol; Maté Biro
Journal:  Hum Vaccin Immunother       Date:  2016-06-20       Impact factor: 3.452

Review 6.  Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors.

Authors:  Gaurav Nayyar; Yaya Chu; Mitchell S Cairo
Journal:  Front Oncol       Date:  2019-02-11       Impact factor: 6.244

Review 7.  The emerging role of epigenetic therapeutics in immuno-oncology.

Authors:  Michael J Topper; Michelle Vaz; Kristen A Marrone; Julie R Brahmer; Stephen B Baylin
Journal:  Nat Rev Clin Oncol       Date:  2019-09-23       Impact factor: 66.675

8.  Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy.

Authors:  Qiyue Hu; Xin Ye; Xiangdong Qu; Dongbing Cui; Lei Zhang; Zhibin Xu; Hong Wan; Lianshan Zhang; Weikang Tao
Journal:  Sci Rep       Date:  2018-05-16       Impact factor: 4.379

9.  Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.

Authors:  Estefanía Paula Juliá; Analía Amante; María Betina Pampena; José Mordoh; Estrella Mariel Levy
Journal:  Front Immunol       Date:  2018-09-20       Impact factor: 7.561

Review 10.  Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.

Authors:  Nayoung Kim; Hun Sik Kim
Journal:  Front Immunol       Date:  2018-09-10       Impact factor: 7.561

View more
  6 in total

Review 1.  Tissue-Resident Innate Immune Cell-Based Therapy: A Cornerstone of Immunotherapy Strategies for Cancer Treatment.

Authors:  Rosalia Busà; Matteo Bulati; Ester Badami; Giovanni Zito; Daniela Claudia Maresca; Pier Giulio Conaldi; Giuseppe Ercolano; Angela Ianaro
Journal:  Front Cell Dev Biol       Date:  2022-05-26

Review 2.  The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies.

Authors:  Hasan Baysal; Ines De Pauw; Hannah Zaryouh; Marc Peeters; Jan Baptist Vermorken; Filip Lardon; Jorrit De Waele; An Wouters
Journal:  Front Immunol       Date:  2021-09-07       Impact factor: 7.561

Review 3.  CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma.

Authors:  Massimiliano Gambella; Simona Carlomagno; Anna Maria Raiola; Livia Giannoni; Chiara Ghiggi; Chiara Setti; Chiara Giordano; Silvia Luchetti; Alberto Serio; Alessandra Bo; Michela Falco; Mariella Della Chiesa; Emanuele Angelucci; Simona Sivori
Journal:  Front Immunol       Date:  2022-02-24       Impact factor: 7.561

Review 4.  Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy.

Authors:  Yang Zhou; Miao Li; Kuangyi Zhou; James Brown; Tasha Tsao; Xinjian Cen; Tiffany Husman; Aarushi Bajpai; Zachary Spencer Dunn; Lili Yang
Journal:  Cancers (Basel)       Date:  2022-05-01       Impact factor: 6.639

Review 5.  Angiogenic Properties of NK Cells in Cancer and Other Angiogenesis-Dependent Diseases.

Authors:  Dorota M Radomska-Leśniewska; Agata Białoszewska; Paweł Kamiński
Journal:  Cells       Date:  2021-06-29       Impact factor: 6.600

Review 6.  Aging of the Immune System: Focus on Natural Killer Cells Phenotype and Functions.

Authors:  Ashley Brauning; Michael Rae; Gina Zhu; Elena Fulton; Tesfahun Dessale Admasu; Alexandra Stolzing; Amit Sharma
Journal:  Cells       Date:  2022-03-17       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.